{
  "ticker": "KNSA",
  "company_name": "Kiniksa Pharmaceuticals, Ltd.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04463004",
      "title": "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "COVID-19, Sars-CoV2, Pneumonia",
      "start_date": "2020-09-02",
      "completion_date": "2020-11-30",
      "enrollment": 0,
      "sponsor": "Virginia Commonwealth University"
    },
    {
      "nct_id": "NCT04687358",
      "title": "REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Recurrent Pericarditis",
      "start_date": "2021-03-16",
      "completion_date": "2026-02",
      "enrollment": 0,
      "sponsor": "Kiniksa Pharmaceuticals International, plc"
    },
    {
      "nct_id": "NCT04447469",
      "title": "Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "COVID",
      "start_date": "2020-07-28",
      "completion_date": "2022-01-14",
      "enrollment": 0,
      "sponsor": "Kiniksa Pharmaceuticals International, plc"
    },
    {
      "nct_id": "NCT03816891",
      "title": "Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Prurigo Nodularis, Pruritis",
      "start_date": "2019-03-11",
      "completion_date": "2023-08-24",
      "enrollment": 0,
      "sponsor": "Genentech, Inc."
    },
    {
      "nct_id": "NCT03858634",
      "title": "A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis",
      "start_date": "2019-05-29",
      "completion_date": "2020-06-08",
      "enrollment": 0,
      "sponsor": "Genentech, Inc."
    },
    {
      "nct_id": "NCT07010159",
      "title": "Phase 2/3 Study of KPL-387 in Recurrent Pericarditis",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Pericarditis, Pericarditis Acute, Recurrent Pericarditis",
      "start_date": "2025-07-25",
      "completion_date": "2029-12-31",
      "enrollment": 0,
      "sponsor": "Kiniksa Pharmaceuticals International, plc"
    },
    {
      "nct_id": "NCT04399980",
      "title": "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "COVID 19, SARS-CoV 2, Pneumonia",
      "start_date": "2020-05-20",
      "completion_date": "2021-04-23",
      "enrollment": 0,
      "sponsor": "The Cleveland Clinic"
    },
    {
      "nct_id": "NCT07288216",
      "title": "Transition to KPL-387 Monotherapy Dosing & Administration Study",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Recurrent Pericarditis, Heart Diseases, Pericarditis",
      "start_date": "2026-01-31",
      "completion_date": "2029-12-31",
      "enrollment": 0,
      "sponsor": "Kiniksa Pharmaceuticals International, plc"
    },
    {
      "nct_id": "NCT04497662",
      "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2019-10-22",
      "completion_date": "2021-03-02",
      "enrollment": 0,
      "sponsor": "Kiniksa Pharmaceuticals, Ltd."
    },
    {
      "nct_id": "NCT03980522",
      "title": "A Pilot Study of KPL-914 in Recurrent Pericarditis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Recurrent Pericarditis",
      "start_date": "2018-01-24",
      "completion_date": "2019-05-17",
      "enrollment": 0,
      "sponsor": "Kiniksa Pharmaceuticals (UK), Ltd."
    }
  ],
  "summary": {
    "total_trials": 15,
    "by_phase": {
      "PHASE2": 10,
      "": 1,
      "PHASE2, PHASE3": 2,
      "PHASE1": 1,
      "PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 11,
      "ACTIVE_NOT_RECRUITING": 1,
      "RECRUITING": 2,
      "TERMINATED": 1
    },
    "active_trials": 3,
    "completed_trials": 11,
    "conditions": [
      "Arthritis, Rheumatoid",
      "COVID",
      "COVID 19, SARS-CoV 2, Pneumonia",
      "COVID-19, Sars-CoV2, Pneumonia",
      "Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis",
      "Giant Cell Arteritis",
      "Healthy Volunteers",
      "Pericarditis, Pericarditis Acute, Recurrent Pericarditis",
      "Prurigo Nodularis, Pruritis",
      "Recurrent Pericarditis",
      "Recurrent Pericarditis, Heart Diseases, Pericarditis",
      "Sj\u00f6grens Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:26.232015",
    "search_query": "Kiniksa Pharmaceuticals, Ltd.",
    "url": "https://clinicaltrials.gov/search?term=Kiniksa+Pharmaceuticals,+Ltd."
  }
}